Dhaka, Bangladesh-based Beximco Pharmaceuticals has signed a distribution deal with Gulf Generics, a drug distributor in the Gulf region, which is owned by the members of the Kuwait Royal Family.
Under the terms of the agreement, Gulf Generics will be responsible for the distribution and marketing of Beximco products to Kuwait and other Gulf Central Committee states, an area whose pharmaceutical market is currently valued at over $2.0 billion.
Nazmul Hassan, Beximco's chief executive, noted that "as part of our global expansion plan, we have always considered the Middle East as a high-potential market and this agreement with Gulf Generics will help us mark our presence in the Gulf region and is further evidence of our commitment to our global growth."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze